Trexquant Investment LP Purchases 201,438 Shares of Evolus, Inc. $EOLS

Key Points

• Trexquant Investment LP increased its holdings in Evolus, Inc. by 122.9% in Q1, owning 365,375 shares valued at approximately $4,395,000.
• Multiple hedge funds have adjusted their positions in Evolus, with Nuveen LLC acquiring a new stake worth about $12,330,000 and Millennium Management increasing its holdings by 29.1%.
• Insider transactions include Director Albert G. White III purchasing 20,000 shares for $189,000, marking a 65.84% increase in his ownership, while CMO Tomoko Yamagishi-Dressler sold 5,722 shares for $42,972.22.

Trexquant Investment LP lifted its position in shares of Evolus, Inc. (NASDAQ:EOLS - Free Report) by 122.9% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 365,375 shares of the company's stock after buying an additional 201,438 shares during the quarter. Trexquant Investment LP owned about 0.57% of Evolus worth $4,395,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Barclays PLC increased its position in shares of Evolus by 12.9% during the fourth quarter. Barclays PLC now owns 105,786 shares of the company's stock worth $1,167,000 after buying an additional 12,124 shares during the period. Frontier Capital Management Co. LLC acquired a new stake in shares of Evolus during the fourth quarter worth $2,648,000. Raymond James Financial Inc. acquired a new stake in shares of Evolus during the fourth quarter worth $575,000. Comerica Bank bought a new position in Evolus during the fourth quarter worth $312,000. Finally, Tang Capital Management LLC boosted its stake in Evolus by 3.1% during the fourth quarter. Tang Capital Management LLC now owns 4,997,399 shares of the company's stock worth $55,171,000 after acquiring an additional 150,000 shares in the last quarter. 90.69% of the stock is currently owned by institutional investors and hedge funds.

Evolus Stock Up 1.8%

Shares of Evolus stock traded up $0.13 during trading hours on Thursday, reaching $7.51. The company's stock had a trading volume of 656,710 shares, compared to its average volume of 1,094,697. Evolus, Inc. has a one year low of $5.71 and a one year high of $17.82. The company has a market capitalization of $485.75 million, a P/E ratio of -7.66 and a beta of 1.07. The stock's fifty day simple moving average is $8.32 and its two-hundred day simple moving average is $10.29. The company has a debt-to-equity ratio of 22.00, a quick ratio of 1.86 and a current ratio of 2.27.

Insider Buying and Selling at Evolus

In other Evolus news, Director Albert G. White III acquired 20,000 shares of the company's stock in a transaction on Monday, June 9th. The shares were purchased at an average cost of $9.45 per share, with a total value of $189,000.00. Following the completion of the purchase, the director owned 50,378 shares of the company's stock, valued at approximately $476,072.10. This represents a 65.84% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider David Moatazedi sold 111,323 shares of the firm's stock in a transaction on Friday, June 13th. The shares were sold at an average price of $10.05, for a total transaction of $1,118,796.15. Following the completion of the transaction, the insider directly owned 381,509 shares in the company, valued at $3,834,165.45. This trade represents a 22.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 133,627 shares of company stock valued at $1,325,764 over the last ninety days. 6.10% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several research analysts recently issued reports on the stock. Needham & Company LLC reissued a "hold" rating and set a $22.00 target price on shares of Evolus in a research note on Wednesday, August 6th. BTIG Research cut their target price on shares of Evolus from $21.00 to $18.00 and set a "buy" rating on the stock in a research note on Wednesday, August 6th. HC Wainwright cut their target price on shares of Evolus from $27.00 to $20.00 and set a "buy" rating on the stock in a research note on Wednesday, August 6th. Finally, Wall Street Zen lowered shares of Evolus from a "hold" rating to a "sell" rating in a research note on Saturday, August 9th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $21.25.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.